Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

SHELTON, Conn., Aug. 5 /PRNewswire/-- Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical analgesic activity. In addition, CR845 infusion triggered a quantitative endocrine biomarker of peripheral kappa opioid receptor activation at the lowest dose tested.

The Phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 resulted in plasma levels at or above the plasma levels of drug expected to be associated with clinical analgesic efficacy.

The Company plans to advance its intravenous formulation of CR845 into Phase II trials later in 2008. Based on the demonstrated safety, tolerability, and bioactivity of this formulation in Phase I, Cara will continue to develop its oral formulation of CR845 for advancement into Phase I.

About CR845

CR845 was designed to be highly selective for the peripheral kappa opioid receptor, with a prolonged duration of action relative to Cara's first generation of peripheral kappa opioids. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intravenous, subcutaneous, o
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)...ACH, Fla., Nov. 7 Most patients wi...toms that signal an oncoming HAE attack giving the...d decrease the morbidity associated with that atta...t the 2009 American College of Allergy, Asthma &am...ition of symptoms such as fatigue and nausea, whic...
(Date:11/6/2009)...ON, Mass., Nov. 6 DUSA P...dermatology company that is developing and marketi...other products focused on patients with common ski...and Chief Executive Officer, will present a corpor...Summit 2009 on Tuesday, November 10, 2009 at 10:00...
(Date:11/6/2009)..., Fla., Nov. 6 Roper In... it has signed a definitive agreement to acquire V...edical devices. The Verathon Board of Directors h...ject to customary regulatory approvals and closing...parties expect the closing to be completed in earl...
Breaking Medicine Technology:Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Beryl Receives Entrepreneurs Foundation of North Texas North Star Recognition 50450 1Beryl Receives Entrepreneurs Foundation of North Texas North Star Recognition 50450 2Winnipeg Veterinary Company Pharm Vet Produces Essential Oil Infused Mosquito Spray Thats a Welcome and Safe Alternative to Controversial Deet Based R 50447 1Save the ta tas Calling on Women to Join the Love Avon Army of Women to Unlock the Key to Breast Cancer Prevention 50445 1Save the ta tas Calling on Women to Join the Love Avon Army of Women to Unlock the Key to Breast Cancer Prevention 50445 2
...cals presented,positive results today from two pha... studies on SPI-452, a novel pharmacokinetic enhan...rmacokinetic enhancers increase drug levels of,co-...me P450 (CYP)-mediated,drug metabolism. These incr...duced pill burden, and reduced daily dosing. Becau...
...ency for International Development (USAID) continu..., who are in the midst of an expanding humanitaria...e cholera epidemic have left the people of Zimbabw...hrough the President,s Malaria Initiative, is supp... shore up gaps in the country,s usually strong spr...
Other Medicine Technology:Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 2Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 3Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 4Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 5USAID Provides Malaria Assistance to Zimbabwe 2
(Date:11/8/2009)..., PHILADELPHIA, Nov. 8 ...lauds the prevention and wellness provisions in th...e. ,, "With passage of this bill, the House tak...orting important insurance reforms and moving our ...e sick to one that focuses on keeping people healt...
(Date:11/8/2009)...oring pain now can take you out of the game later,...ay News) -- Foot injuries are the talk of the NFL ...Eli Manning and running back Willie Parker. , O...tion and American Academy of Podiatric Sports Medi...et when they play fall sports like football and la...
(Date:11/8/2009)... New book called "Preve...quot; by Dr. Roberto Giraldo shows that AIDS is a ...to a variety of so-called immune system stressor a...ritional and most of all, emotional. , ...9 -- From Nov. 6 – 8, 2009, cell biologists,...
(Date:11/8/2009)... A jury of 8 people in the W...unty woman $2,300,000 in pain and suffering for a ...y, James Tallman and Alicia Nocera of Thomas E. Cr...lf of the plaintiff, Vita Monestersky and against ...emergency total abdominal hysterectomy at age 18. ...
(Date:11/8/2009)..., WASHINGTON, Nov. 7 U...ble Health Care for America Act, which will make h...urance companies accountable and increase access t...public option. ,, "Teddy Roosevelt, FDR and Har...irector Alan Charney. "Today,s vote ranks among ou...
Breaking Medicine News(10 mins):Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2
...ofits Receive the GlaxoSmithKline 12th Annual IMPA...line, one of the world,s leading research-based ph...ed the recipients of the GlaxoSmithKline 12th Annu...ll be held on Tuesday, March 17 at GlaxoSmithKline...
... provides the energy and nutritional benefits from...cts and is now available without a prescription , ... over-the-counter iron supplement that offers both...Bifera provides two types of iron in one small pil...
...AKE CITY, Jan. 19 The 66th Annual Golden Globe Aw...reswhite Supreme" whitened smiles this year thanks...rly Hills, California this weekend. Guests of the ...he lounge supported the Visual Impact Now organiza...
...tor Online is the only authorized online learning .... 19 Known for bringing innovation to the chiropr...introduced the industry,s only web-based seminar p...hods to teach doctors, students and healthcare pro...
...s to increase physician EHR adoption, interoperabi...exchange , , TAMPA, Fla., Jan. 19 South Jersey H...ffering hospital services, ambulatory care service...cians through eHealth Connection, SJH,s EHR Grant ...
...fit doesn,t have to break the bank, experts say , ...ryone needs to make sacrifices during hard economi...alth. , Experts with the Dana-Farber Cancer Instit..., Get moving . Moderate to intensive aerobic exer...
Other Medicine News:Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 2Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 3Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 4Health News:First-Ever Over-the-Counter Dual Action Iron Supplement Available at Major Retail Outlets in the United States; Bifera is a New, Innovative Dual Iron Supplement Now on the Market 2Health News:Photos: Opalescence Treswhite Supreme Adds Glimmer to 'Twilight' Film Actor's Smile 2Health News:Activator Methods Introduces Web-Based Seminar Program 2Health News:South Jersey Healthcare Offers Sage Intergy EHR Electronic Health Records System to Community Physicians Through EHR Grant Program 2Health News:South Jersey Healthcare Offers Sage Intergy EHR Electronic Health Records System to Community Physicians Through EHR Grant Program 3Health News:Low-Cost Strategies to Maintain Health in Hard Times 2
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: